Latest Breaking News On - Chiasma data - Page 1 : comparemela.com

Pfizer, Inc. (NYSE: PFE) and Myovant Sciences (NYSE: MYOV) announced FDA approval for once-daily Myfembree, relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg, for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women, with a treatment duration of up to 24 months. The companies said they will jointly commercialize Myfembree in the U.S. Myfembree is expected to be available in June. Pfizer shares edged down 0.15% to $38.86 in after-hours trading and Myovant receded 0.34% to $23.60. Zosano Announces Publication Of Positive Results From Long-Term Use Of Migraine Drug Zosano Pharma Corporation (NASDAQ: ZSAN) announced that an article titled, Long Term Safety, Tolerability, and Efficacy of Intracutaneous Zolmitriptan (M207) in the Acute Treatment of Migraine was published in the Journal of Headache and Pain

United statesTimothy springerAscendis pharmaAlex kellyAnpac bioPeter traberScience co ltdBiotechnology corporationOcugen incRedhill biopharma ltdPfizer incAbbvie incFite biopharma ltdSingular genomics systems incBausch health to reduce debtTeva pharmaceutical industries limited